Explore
Validate
Learn
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [8]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- V2048 - Provider product page
- Provider
- NSJ Bioreagents
- Product name
- CD20 Antibody
- Antibody type
- Monoclonal
- Antigen
- The lymphoblastoid cell line Daudi was used as the immunogen for this CD20 antibody.
- Description
- Protein G purified antibody
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Antibody clone number
- B9E9
- Vial size
- 20 µg, 100 µg (with sodium azide), 100 µg (without sodium azide), 7 ml (prediluted for IHC use, if applicable)
- Storage
- Store the CD20 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).
Submitted references Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival.
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma.
Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review.
Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab.
Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways.
Expression of calcium-permeable cation channel CD20 accelerates progression through the G1 phase in Balb/c 3T3 cells.
Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes.
Phosphorylation of the B1 (CD20) molecule by normal and malignant human B lymphocytes.
Johnson NA, Boyle M, Bashashati A, Leach S, Brooks-Wilson A, Sehn LH, Chhanabhai M, Brinkman RR, Connors JM, Weng AP, Gascoyne RD
Blood 2009 Apr 16;113(16):3773-80
Blood 2009 Apr 16;113(16):3773-80
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma.
Forero A, Weiden PL, Vose JM, Knox SJ, LoBuglio AF, Hankins J, Goris ML, Picozzi VJ, Axworthy DB, Breitz HB, Sims RB, Ghalie RG, Shen S, Meredith RF
Blood 2004 Jul 1;104(1):227-36
Blood 2004 Jul 1;104(1):227-36
Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review.
Kennedy GA, Tey SK, Cobcroft R, Marlton P, Cull G, Grimmett K, Thomson D, Gill D
British journal of haematology 2002 Nov;119(2):412-6
British journal of haematology 2002 Nov;119(2):412-6
Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab.
Pickartz T, Ringel F, Wedde M, Renz H, Klein A, von Neuhoff N, Dreger P, Kreuzer KA, Schmidt CA, Srock S, Schoeler D, Schriever F
Experimental hematology 2001 Dec;29(12):1410-6
Experimental hematology 2001 Dec;29(12):1410-6
Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways.
Mathas S, Rickers A, Bommert K, Dörken B, Mapara MY
Cancer research 2000 Dec 15;60(24):7170-6
Cancer research 2000 Dec 15;60(24):7170-6
Expression of calcium-permeable cation channel CD20 accelerates progression through the G1 phase in Balb/c 3T3 cells.
Kanzaki M, Shibata H, Mogami H, Kojima I
The Journal of biological chemistry 1995 Jun 2;270(22):13099-104
The Journal of biological chemistry 1995 Jun 2;270(22):13099-104
Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes.
Bubien JK, Zhou LJ, Bell PD, Frizzell RA, Tedder TF
The Journal of cell biology 1993 Jun;121(5):1121-32
The Journal of cell biology 1993 Jun;121(5):1121-32
Phosphorylation of the B1 (CD20) molecule by normal and malignant human B lymphocytes.
Tedder TF, Schlossman SF
The Journal of biological chemistry 1988 Jul 15;263(20):10009-15
The Journal of biological chemistry 1988 Jul 15;263(20):10009-15
No comments: Submit comment
No validations: Submit validation data